Will Tyruko save MS patients money? Maybe.
The late August approval of Tyruko (natalizumab-sztn) by the U.S. Food and Drug Administration is big news in the multiple sclerosis world. Tyruko is a biosimilar for Tysabri (natalizumab), and it’s the first biosimilar to gain FDA approval as an MS disease-modifying therapy (DMT). “Tyruko has the potential to extend the reach of natalizumab treatment for [MS] patients, increase healthcare savings and fuel innovation through competition in the market,” Keren…Continue Reading